Cancer Therapy
BMS-275183 showed promising antitumor activity
Published in Cancer Weekly, May 29th, 2006
According to a study from the Netherlands, "BMS-275183 is an orally administered C-4 methyl carbonate analogue of paclitaxel. We did a dose-escalating phase I study to investigate its safety, tolerability, pharmacokinetics, and possible antitumor activity."
"A cycle consisted of 4 weekly doses of BMS-275183. The starting dose was 5 mg, which was increased by 100% increments (i.e., 5, 10, 20 mg/m2, etc.) in each new cohort consisting of 1 patient. Cohorts were expanded when toxicity was encountered, and 20 patients were treated at the maximum tolerated dose (MTD). Plasma pharmacokinetics were...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
Source: Cancer Weekly (2006-05-29)
More Articles from Cancer Weekly
- Hepatocarcinogenesis
Hepatocarcinogenesis linked to dysregulation of the Hedgehog pathway - Lung Cancer
Lung carcinogenesis linked to reduced HAUSP gene expression - Ovarian Cancer
Epithelial ovarian cancer survival lowered with stromal matrix metalloproteinase overexpression - AIDS-Related Kaposi Sarcoma
MMP inhibitor COL-3 active and well tolerated in AIDS-related Kaposi sarcoma - Acoustic Neuroma
Acoustic neuroma long-term outcome after stereotactic radiosurgery assessed - Acute Myelogenous Leukemia
PBSCT well tolerated and feasible in older patients with acute myelogenous leukemia - More from this issue of Cancer Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
